Navigation Links
NeurogesX to Present at J.P. Morgan Health Care Conference
Date:1/16/2010

SAN MATEO, Calif., Jan. 7 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, President and Chief Executive Officer, is scheduled to present at the 28th Annual J.P. Morgan Healthcare Conference, to be held January 11-14, 2009 at the Westin St. Francis Hotel in San Francisco, California.

Mr. DiTonno and Stephen Ghiglieri, Chief Financial Officer, will be available to respond to questions during a 25-minute breakout session immediately following the presentation, and to participate in one-on-one meetings with investors attending the conferences.


    Event:  28th Annual J.P. Morgan Healthcare Conference
    Date:   Thursday, January 14, 2009
    Time:   12:30 p.m. PT
    Place:  Westin St. Francis Hotel, San Francisco, CA (Elizabethan A/B)

The presentation will be webcast live and can be accessed by visiting the investor relations section of NeurogesX' website at www.neurogesx.com. The webcasts will be archived for 90 days.

About NeurogesX, Inc.

NeurogesX, Inc. (Nasdaq: NGSX) is a San Francisco Bay Area-based biopharmaceutical company focused on developing and commercializing novel pain management therapies. NeurogesX was founded on the concept that use of prescription strength capsaicin could help manage the pain associated with neuropathic pain conditions. Since its inception, NeurogesX has leveraged its passion to help people with pain to efficiently develop this concept and is now poised to bring its lead product to patients and physicians. In addition, we continue to apply our knowledge and expertise in the development of other novel treatments for pain.

The Company's lead product, Qutenza® (capsaicin) 8% patch, is a dermal delivery system containing a prescription strength of capsaicin that is currently approved in the United States and the European Union. NeurogesX expects to launch Qutenza in United States in the first half of 2010 for patients with postherpetic neuralgia (PHN). In Europe, Qutenza will be marketed by Astellas Pharma Europe Ltd., (Astellas), the European subsidiary of Tokyo-based Astellas Pharma Inc.

The Company's second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies.

The Company's early stage product pipeline includes pre-clinical compounds which are prodrugs of acetaminophen and various opioids. The Company has evaluated these compounds in vitro and in vivo.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include but are not limited to: statements about the safety and efficacy of Qutenza®; the timing of launch of Qutenza; and development activities for NGX-1998 and other product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: any regulatory approvals which are received may be limited to certain indications; Qutenza and NeurogesX' other product candidates may have unexpected adverse side effects; difficulties or delays in the launch and commercialization of Qutenza; and the outcomes of any submissions to the FDA for NeurogesX' product candidates. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.


    NeurogesX, Inc.
    Stephen Ghiglieri
    Chief Financial Officer
    (650) 358-3310

    The Ruth Group
    Sara Pellegrino (investors)
    (646) 536-7002
    spellegrino@theruthgroup.com

    Jason Rando (media)
    (646) 536-7025
    jrando@theruthgroup.com
    -----------------------

SOURCE NeurogesX, Inc.

RELATED LINKS
http://www.neurogesx.com

'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. NeurogesX to Present at Piper Jaffray Health Care Conference
2. NeurogesX Reports Third Quarter 2009 Results
3. NeurogesX to Present at Two November Conferences
4. NeurogesX to Present at UBS Global Life Sciences Conference
5. NeurogesX to Present at Upcoming Fall Conferences
6. NeurogesX Appoints New Board Director and Audit Committee Chairman
7. NeurogesX Reports Second Quarter 2009 Results
8. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
9. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
10. NeurogesX Added to Russell 3000 Index
11. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... (PRWEB) , ... July 26, 2017 , ... ... Us Research Program at the National Institutes of Health (NIH), will be one ... This annual conference provides a platform for a multi-stakeholder discussion on the latest ...
(Date:7/25/2017)... Falls, Wisconsin (PRWEB) , ... July 25, 2017 , ... ... for the food and beverage industry, offers Citri-Fi® 125. This natural citrus fiber is ... to thicken and extend real tomato in sauces, condiments and spreads. Today, more than ...
(Date:7/24/2017)... ... July 24, 2017 , ... Charm Sciences, Inc. is pleased to announce ... Conference on Interstate Milk Shipments (NCIMS) Laboratory Committee and Appendix N Committee as a ... 1, 2017. , The NCIMS voted at its annual meeting in April, 2015 to ...
(Date:7/24/2017)... (PRWEB) , ... July 24, ... ... Analyst, Kenny Soulstring, today announced that the stock market news outlet had ... risk assessment diagnostic testing that screens and identifies exposure, progression and risk ...
Breaking Biology Technology:
(Date:4/5/2017)... April 5, 2017 Today HYPR Corp. ... the server component of the HYPR platform is officially ... the end-to-end security architecture that empowers biometric authentication across ... has already secured over 15 million users across the ... of connected home product suites and physical access represent ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities ... (physiological and behavioral), by technology (fingerprint, AFIS, iris recognition, ... recognition, and others), by end use industry (government and ... immigration, financial and banking, and others), and by region ... , Asia Pacific , and ...
Breaking Biology News(10 mins):